RESEARCH ALLIANCE CORPORATION IV ANNOUNCES PRICING OF $75 MILLION INITIAL PUBLIC OFFERING

Research Alliance Corporation IV, a special purpose acquisition company (SPAC), has announced the pricing of its initial public offering (IPO) of 7,500,000 Class A ordinary shares at $10.00 per share. The offering is expected to close on July 14, 2026, and the shares will begin trading on the Nasdaq Capital Market under the ticker symbol "RACD." This IPO aims to raise a total of $75 million, positioning Research Alliance Corporation IV to pursue strategic acquisitions within the healthcare sector.

Founded and sponsored by an affiliate of RA Capital Management, L.P., Research Alliance Corporation IV is led by CEO Matthew Hammond, PhD, MBA, and Chief Business Officer/Chief Operating Officer Henry Stusnick. The company is designed to identify and merge with a target business in the healthcare or healthcare-related industries, leveraging the management team's expertise to enhance its competitive advantage. This focus aligns with growing investor interest in the healthcare sector, particularly as the industry continues to evolve post-pandemic, presenting numerous opportunities for innovation and consolidation.

The IPO has attracted significant participation from a range of institutional investors, including Adage Capital Partners LP, Venrock Healthcare Capital Partners, and Janus Henderson Investors, among others. This diverse backing underscores the confidence in the company’s strategy and the potential for lucrative returns in the healthcare domain. The involvement of prominent investment firms also reflects a broader trend of capital flowing into healthcare-focused SPACs, as investors seek to capitalize on the sector's resilience and growth prospects.

As the healthcare landscape becomes increasingly complex, driven by technological advancements and changing regulatory environments, Research Alliance Corporation IV is well-positioned to identify and execute on strategic opportunities. The management's commitment to focusing on healthcare-related businesses may provide a distinct advantage in navigating this dynamic environment. The successful completion of this IPO could serve as a catalyst for further SPAC activity in the healthcare sector, as other companies look to replicate this model and capitalize on similar market conditions.

In conclusion, the IPO of Research Alliance Corporation IV marks a significant step in the ongoing trend of SPACs entering the public markets, particularly within the healthcare sector. With a robust strategy and strong institutional backing, the company is poised to make impactful acquisitions that could reshape its future and contribute to the overall growth of the healthcare industry. As the market continues to evolve, the performance of this offering will be closely monitored by investors and analysts alike, potentially influencing future SPAC activity in the sector.